Skip to main content
. 2020 Oct;8(19):1223. doi: 10.21037/atm-20-2444

Figure 1.

Figure 1

Enrollment flowchart. After inclusion and exclusion, 8,310 compensated liver cirrhotic patients with low-risk EV enrolled in our study from January 2001 to February 2018. After excluding patients who had undergone prophylactic therapy with EVL, the remaining 6,803 patients without NSBB prophylaxis were the main group for primary endpoint analysis. The minor group was 281 matched patients (3.97%) with NSBB prophylaxis for secondary endpoint analysis. EV, esophageal variceal; EVL, endoscopic variceal ligation; NSBB, non-selective beta-blockers.